Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (Q79950167)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

chronic myeloid leukemia

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Jabbour E

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Kantarjian H

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Jones D

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Talpaz M

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Bekele N

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

O'Brien S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Zhou X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Luthra R

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Garcia-Manero G

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Giles F

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Rios MB

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Cortes J

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

20 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

1767-1773

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855631%20AND%20SRC:MED&resulttype=core&format=json

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404318

7 January 2021